J. D. West

NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients

H. Lenz, V. Heinemann, Taline Khoukaz, 2018, PloS one.

Title: Clinical significance of TLR1 I602S polymorphism for patients with metastatic colorectal cancer treated with FOLFIRI plus bevacizumab Authors:

H. Lenz, V. Heinemann, S. Okazaki, 2016 .

Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab

H. Lenz, V. Heinemann, S. Okazaki, 2016, Molecular Cancer Therapeutics.

Single nucleotide polymorphisms in the IGF‐IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE‐3 trial

A. Barzi, H. Lenz, V. Heinemann, 2017, International journal of cancer.

Predictive value of TLR7 polymorphism for cetuximab‐based chemotherapy in patients with metastatic colorectal cancer

H. Lenz, V. Heinemann, S. Okazaki, 2017, International journal of cancer.

Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab

H. Lenz, V. Heinemann, S. Okazaki, 2016, Molecular Cancer Therapeutics.

Title: Clinical significance of TLR1 I602S polymorphism for patients with metastatic colorectal cancer treated with FOLFIRI plus bevacizumab

H. Lenz, S. Okazaki, Dongyun Yang, 2016 .